       Document 0030
 DOCN  M9620030
 TI    Pharmacokinetics and bioavailability of fluconazole in two groups of
       males with human immunodeficiency virus (HIV) infection compared with
       those in a group of males without HIV infection.
 DT    9602
 AU    Tett S; Moore S; Ray J; Clinical Pharmacology and Toxicology, St.
       Vincent's Hospital,; Darlinghurst, New South Wales, Australia.
 SO    Antimicrob Agents Chemother. 1995 Aug;39(8):1835-41. Unique Identifier :
       AIDSLINE MED/96100759
 AB    Fluconazole pharmacokinetics, including absolute bioavailability, were
       determined for one group of controls (n = 10) and two groups of people
       with human immunodeficiency virus (HIV) infection (those with CD4+
       T-cell counts of less than [n = 4] or greater than [n = 9] 200 cells per
       mm3). Twenty subjects received four doses of fluconazole; three doses
       were oral (50, 100, and 400 mg), and one dose was intravenous (either
       50, 100, or 400 mg). The other three subjects received one or two doses.
       The groups were comparable in terms of the weight, body mass index, and
       estimated creatinine clearance of the subjects, but the people with HIV
       infection were older. Pharmacokinetic parameters indicated linearity in
       all subjects; the area under the plasma concentration-time curve and the
       maximum concentration increased in proportion to the dose. The fraction
       of an oral dose of fluconazole absorbed approximated unity in all three
       groups of subjects. The mean (+/- standard deviation) plasma clearance
       of fluconazole was lowest in the group of subjects with low CD4+ T-cell
       counts; the value for this group was 0.74 +/- 0.19 liter/h, compared
       with 0.97 +/- 0.19 liter/h in the group with HIV infection and CD4+
       T-cell counts of greater than 200 cells/mm3 and 1.18 +/- 0.23 liter/h in
       the group of control subjects (P < 0.05). The volume of distribution was
       lower in those with HIV infection (P = 0.04, corrected for weight). The
       half-life was longest in people with HIV infection and low CD4+ T-cell
       counts (P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Administration, Oral  Adolescence  Adult  Biological Availability
       Comparative Study  CD4 Lymphocyte Count  Fluconazole/*PHARMACOKINETICS
       Human  HIV Infections/BLOOD/*METABOLISM  Injections, Intravenous  Male
       Middle Age  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

